Amyotrophic lateral sclerosis: Transgenic model and novel neuroprotective agent

Neuroscience Research Communications

Volumn 26, Issue 3, 2000, Pages 215-226

  Kaddurah Daouk, R ^a,b   Matthews, R ^c   Beal, M Flint ^d  

^a Avicena Group   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Amyotrophic Lateral Sclerosis; Animal models; Creatine; Kinase

Indexed keywords

ADENOSINE TRIPHOSPHATE; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN MITOCHONDRION; GENE MUTATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; REVIEW; TRANSGENIC MOUSE;

EID: 0033919047     PISSN: 08936609     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6769(200005/06)26:3<215::AID-NRC9>3.0.CO;2-Z     Document Type: Review

References (39)

1. Brown RH Jr. Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice. Cell 1995;80:687-692.
2. Mulder DW. Clinical limits of Amyotrophic lateral sclerosis. In: Rowland LP editor. Human motor neuron diseases. New York: Raven Press;1982. p 15-22.
3. Emery AEH and Holloway S. Familial motor neuron disease. In Rowland LP, editor. Human motor neuron diseases. New York: Raven Press;1982. p 139-147.
4. Siddique T. Molecular genetics in amyotrophic lateral sclerosis. In Rowland LP, editor. Amyotrophic lateral sclerosis and other motor neuron disease. Adv Neurol 1991;56:227-231.
5. Hirano A. Cytopathology of amyotrophic lateral sclerosis. Adv Neurol 1991;56:91-101.
6. Rosen DR, Siddique T, Patterson D, et al, Mutations in Cu, Zn superoxide dismutase gene are associated with familial amytrophic lateral sclerosis. Nature 1993;362:59-62.
7. Deng HX, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and strcutural defects in Cu, Zn superoxide dismutase. Science 1993;261:1047-1051.
8. Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993;61:2322-2325.
9. Reaume AG, Sosa PA de, Kulkarni S. et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Gent 1996;13:43-47.
10. Andersen PM, Nilsson P, Ala-Hurula, et.al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet 1995;10:61-66.
11. Rosen et al. Mutations in Cu, Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362: 59-62.
12. Gurney ME, Pu H, Chiu AY, Dal-Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng H-X, Chen W, Zhai P, Sufit RL, Siddique T. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994;264:1772-1775.
13. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U.S.A. 1995;92:689-693.
14. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-1116.
15. Gurey ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice expressing a human Cu, Zn superoxide dismutase mutation. Science 1994;264:1772-1775.
16. Gurney ME. Transgenic animal models of familial amyotrophic lateral sclerosis. J Neurol 1997;244:S15-S20.
17. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. Journal of Neurological Sciences 1997;152:S67-S73.
18. Tu Pang-hsien, Gurney ME, Julien JP, Lee VMY and Trojanowski JQ. Oxidative stress, mutant SOD1 and neurofilament pathology in transgenic mouse models of human motor neuron disease. Laboratory Investigation 1997;76:441-456.
19. Hodgson EK, Fridovich I. The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: inactivation of the enzyme. Biochem 1975;14:5294-5299.
20. Yim MB, Chock PB, Stadtman ER. Copper, zinc superoxide dismutase catalyzes hydroxyl radical production from hydrogen peroxide. Proc Natl Acad Sci USA 1990;87:5006-5010.
21. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993;364:584-586.
22. Wiedau-Pazos M, Goto JJ, Rabizadeh S, et al. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 1996;271:515-518.
23. Yim MB, Kang JH, Yim HS, Kwak HS, Chock PB, Stadtman ER. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu, Zn superoxide dismutase mutant: an enhancement of free radical formation due to an increase in Km for hydrogen peroxide. Proc Natl Acad Sci USA 1996;93:5709-5714.
24. Andrus PK, Fleck TJ, Gurney M, Hall ED. Protein oxidative damage in a transgenic mouse model of familial amytrophic lateral sclerosis. J Neurochem 1998;71:2041-2048.
25. Hall ED, Andrus PK, Oostveen JA, Fleck TJ and Gurney M. Relationship of oxygen radical-induced lipid peroxidation damage to disease onset and progression in a transgenic model of familial ALS. J Neuroscience Res 1998;53:66-67.
26. Dal Canto MC and Gurney ME. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 1994;145:1271-1280.
27. Dal Canto MC and Gurney ME. Neuropathological changes in two lines of mice carrying the mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: A model of familial amyotrophic lateral sclerosis (FALS). Brain Res 1995;676:25-40.
28. Mourelatos Z, Gonatas NK, Stieber A, Gurney ME and Dal Canto MC. The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu, Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease. Proc Natl Acad Sci USA 1996;93:5472-5477.
29. Tu PH, Raju P, Robinson KA, Gurney ME, Trojanowski JQ, and Lee VMY. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resemb;ing human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci USA 1996;93:3155-3160.
30. Albin RL, Greenamyer JT. Alternative excitotoxic hypotheses. Neurol 1992;42:733-737.
31. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-130.
32. Beal MF. Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-359.
33. Cari MT et al. Expression of a Cu, Zn superoxide dismutase typical of familial ALS induces mitochondrial alteration and increase of cytosolic Ca concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett 1997;414:365-368.
34. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the phosphocratinr circuit for cellular energy homeostasis. Biochem J 1992;281:21-40.
35. Wyss M and Kaddurah-Daouk R. Creatine and Creatinine metabolism. Ann Rev of Physiology in press.
36. Chen L, Roberts R, Friedman DL. Expression of brain-type creatine kinase and ubiquitous mitochondrial creatine kinase in the fetal rat brain: evidence for a nuclear energy shuttle. J Comp Neurol 1995;363:389-401.
37. Brdiczka D, Kaldis P, Wallimann T. Invitro complex formation between the octamer of mitochondrial creatine kinase and porin. J Biol Chem 1994;269:27640-27644.
38. O'Gorman et al. The role of creatine kinase inhibition in mitochondrial permeability transition. FEBS Lett 1997;414:253-257.
39. Kliveny P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, and Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine 1999;5:347-350.